CB Insights’ Post

The targeted therapy market is poised for significant growth, with its size increasing from $97.72 billion in 2023 to $105.06 billion in 2024, at a CAGR of 7.5%. The market is expected to reach $140.77 billion by 2028, growing at a CAGR of 7.6%. Key trends include AI integration in drug discovery, increased patient advocacy, companion diagnostics, and regulatory support. Major companies in the market are Pfizer, Johnson & Johnson, AbbVie, Bayer, Novartis, Sanofi, and Gilead Sciences. Notably, Novartis launched Pluvicto, an FDA-approved targeted radioligand therapy, in March 2022, and Bristol Myers Squibb acquired Turning Point Therapeutics in August 2022 to enhance its precision oncology portfolio. Read more https://lnkd.in/gNfC_8xZ #Healthcare #Biotech #CancerTreatment #PrecisionMedicine #MarketTrends #marketresearch #marketintelligence #marketreport #industryanalysis #TheBusinessResearchCompany #TBRC 

🔍 Exciting Breakthroughs in Cancer Treatment and Drug Development! 🚀 This weekly digest from The Babak Lab covers the latest in cutting-edge research, AI-driven drug development, and advanced technologies like CRISPR and nanotechnology. Whether you're passionate about healthcare innovation or looking to stay informed on the latest medical advancements, these insights are not to be missed. Check it out to discover how these breakthroughs are shaping the future of medicine and offering hope for more effective treatments! #CancerResearch #AIinHealthcare #FutureOfMedicine

Collaboration on Flow Cytometry-Based Companion Diagnostics to Advance Personalized Health Care.  www.bd.com BD and Quest Diagnostics, a leader in diagnostic information services, announced a global collaboration agreement to develop, manufacture and commercialize flow cytometry-based companion diagnostics (CDx) intended to help select the best treatment for patients with cancer and other diseases. Together, BD and Quest will aim to provide the pharmaceutical industry with an end-to-end solution for CDx development. The joint offerings will range from exploratory panel development to the manufacturing and distribution of FDA-approved diagnostic kits. Using companion diagnostics to help select a first-line therapy for cancer patients can be critical to ensuring the best outcomes and cost savings. Today's companion diagnostic tests commonly involve technologies such as immunohistochemistry (IHC), fluorescence in situ hybridization (FISH), polymerase chain reaction (PCR), next-genera

Collaboration on Flow Cytometry-Based Companion Diagnostics to Advance Personalized Health Care.  www.bd.com BD and Quest Diagnostics, a leader in diagnostic information services, announced a global collaboration agreement to develop, manufacture and commercialize flow cytometry-based companion diagnostics (CDx) intended to help select the best treatment for patients with cancer and other diseases. Together, BD and Quest will aim to provide the pharmaceutical industry with an end-to-end solution for CDx development. The joint offerings will range from exploratory panel development to the manufacturing and distribution of FDA-approved diagnostic kits. Using companion diagnostics to help select a first-line therapy for cancer patients can be critical to ensuring the best outcomes and cost savings. Today's companion diagnostic tests commonly involve technologies such as immunohistochemistry (IHC), fluorescence in situ hybridization (FISH), polymerase chain reaction (PCR), next-genera

Immuno-Oncology Clinical Trials Market Outlook and Geography Forecast till 2031 Global Immuno-Oncology Clinical Trials Market Size, Share & Trends Analysis Report By Design (Observational Trials, Interventional Trials) By Phase (Phase I, Phase IV, Phase II, Phase III) By Indication (Solid Tumors, Hematological Cancer), Global Economy Insights, Regional Outlook, Growth Potential, Price Trends, Competitive Market Share & Forecast, 2023 - 2031 IMIR Market Research Pvt. Ltd. 📚 𝐆𝐞𝐭 𝐭𝐡𝐢𝐬 𝐫𝐞𝐩𝐨𝐫𝐭 𝐚𝐭 𝐝𝐢𝐬𝐜𝐨𝐮𝐧𝐭𝐞𝐝 𝐩𝐫𝐢𝐜𝐞:👇 https://lnkd.in/d5Tu8AGZ 📚𝐓𝐨𝐩 𝐌𝐨𝐫𝐞 𝐊𝐞𝐲 𝐏𝐥𝐚𝐲𝐞𝐫𝐬 𝐀𝐫𝐞::👇 AbbVie ADAPTIMMUNE THERAPEUTICS PLC Alkermes Amgen Arcus Biosciences AstraZeneca, BioAtla, Inc. BioNTech SE Boehringer Ingelheim Bristol Myers Squibb Celgene  Compugen CytoDyn Daiichi Sankyo, Inc. Dynavax Technologies Elevation Strategic Development, LLC Eli Lilly and Company EMD Serono, Inc.  Excelya Exelixis Exscientia Fate Therapeutics Inc Genentech  Gilead Sciences GSK Immunomedics  Incyte Iovance Biotherapeutics, Inc. Johnson & Johnson Kite Pharma  Labcorp Drug Development MacroGenics, Inc. Medpace Merck Group. Mirati Therapeutics Mustang Bio Nektar Therapeutics Novartis #immunooncology #immunotherapy #immunology #cancertreatment #cancerresearch #cancer #targetedtherapy #cancerawareness #cancerimmunotherapy #precisionmedicine #oncologist #cancerfighter #cancersupport #survivorship #immunotherapytrials #oncology #hopeforcancer #fightagainstcancer #immunotherapysuccess #tumorresponse #doctorrishisharma #lifewithcancer #cancerspecialist #metastaticbreastcancer #metastaticcancer #medical #immunotherapyresearch #oncologyresearch #laboratory #metastaticbreastcancerawareness

The PD-L1 biomarker testing market is rapidly evolving, driven by advances in cancer immunotherapy and precision medicine. Here's a snapshot of some key players shaping this dynamic market: 🔬 Agilent Technologies: Leading the charge with cutting-edge analytical technologies for accurate PD-L1 testing. #AgilentTechnologies 🔬 Roche: Innovating with its comprehensive portfolio of diagnostic assays and solutions, advancing personalized treatment strategies. #Roche 🔬 Merck: Pioneering in biomarker testing with its robust research and development efforts, contributing to better patient outcomes. #Merck 🔬 Bristol-Myers Squibb: Leveraging its expertise in immuno-oncology to drive advancements in PD-L1 biomarker testing. #BristolMyersSquibb 🔬 AstraZeneca: Investing in novel approaches to enhance the accuracy and efficiency of PD-L1 biomarker testing. #AstraZeneca 🔬 Ono Pharmaceutical: Bringing innovative testing solutions to support its expanding oncology portfolio. #OnoPharmaceutical 🔬 Regeneron: Focused on integrating advanced biomarker testing into its research pipeline for targeted therapies. #Regeneron 🔬 Innovent: Enhancing testing methodologies to support its growing oncology pipeline. #Innovent 🔬 Hengrui Medicine: Committed to advancing PD-L1 biomarker testing through its innovative research efforts. #HengruiMedicine 🔬 Junshi Biosciences: Driving progress in biomarker testing with a focus on precision medicine and cancer treatment. #JunshiBiosciences #HealthcareInnovation #ImmunoOncology #BiomarkerTesting #PrecisionMedicine #CancerResearch #MarketTrends #MedicalDevices #Diagnostics Read Report @ https://lnkd.in/gwqiiMiH

#WeeklyDigest Upgrading Cancer Treatment and Drug Development 🚀 Stay ahead in the fight against cancer and the forefront of pharmaceutical innovation with this week’s highlights by The Babak Lab. Learn about groundbreaking research, cutting-edge technologies, and transformative AI applications poised to redefine treatment paradigms. Whether you’re a healthcare professional, a researcher, or someone passionate about medical advancements, these insights will inspire and inform. 🔥 Revolutionizing Treatment for Deadly Triple-Negative Breast Cancer This research could significantly accelerate the availability of safe and effective treatments for TNBC patients, a group with limited options. 🔗 Read more: https://lnkd.in/gEUfD3Y6 💻 AI is Transforming Drug Development AI’s ability to streamline drug development promises faster, cheaper, and more personalized treatment options, potentially revolutionizing the pharmaceutical industry. 🔗 Read more: https://lnkd.in/ga2ATGqw 🛠 Discover the Cutting-Edge Technologies in Cancer Care The integration of advanced technologies is transforming cancer care, offering hope for more efficient, precise, and effective treatments. 🔗 Read more: https://lnkd.in/gJ4f_cA9 Stay tuned for more breakthroughs in cancer research and drug development. Let's continue to support and celebrate innovations that bring us closer to effective treatments and improved patient outcomes. #CancerResearch #BreastCancerAwareness #AIinHealthcare #DrugDevelopment #Biotechnology #PharmaceuticalInnovation #MedicalResearch #GeneEditing #Nanotechnology #HealthcareInnovation #FutureOfMedicine #CancerTreatment #ClinicalTrials #PrecisionMedicine #HealthTech

Finding the right dose for an oncology compound could be the utmost single important and challenge task in the drug development. Thoughtful study designs, exposure information, translational data, and statistical modeling play an increasingly important role. The proposed "three steps toward dose optimization" procedure (https://lnkd.in/gvd76D9Q) provides some efficient fit for purpose designs and analyses that can increase the likelihood and reduce the uncertainty of selecting an optimal dose for a registration trial that demonstrates a balanced safety and efficacy profile.

Significant milestones achieved by AbbVie | A global biopharmaceutical innovator company addressing several unmet medical needs, and focusing in the fields of immunology, oncology, neuroscience, virology, and women's health. Firstly, in the ADC world (since we love it so much) the U.S. Food and Drug Administration has granted full approval for ELAHERE™ (mirvetuximab soravtansine-gynx), expanding treatment options for certain patients with ovarian cancer. ELAHERE™ is an antibody-drug conjugate that targets the folate receptor alpha, commonly found on ovarian cancer cells. This approval follows positive results from clinical trials demonstrating its efficacy and safety in advanced ovarian cancer patients who have undergone multiple lines of therapy. AbbVie's commitment to developing novel treatments for cancer patients is underscored by this significant achievement today. In another strategic move, AbbVie has announced its acquisition of Landos Biopharma, further strenghtening its portfolio in inflammatory and autoimmune diseases. This acquisition aligns with AbbVie's ongoing efforts to address unmet medical needs in the therapeutic areas mentioned above. Landos Biopharma, Inc. brings innovative drug candidates and a proprietary platform for the development of oral therapeutics targeting autoimmune diseases. As the company continues to expand its capabilities, portfolio and offerings, patients can look forward to advanced treatment options and improved outcomes (precision medicine) across a range of medical conditions. Source: https://lnkd.in/d2H76KZi https://lnkd.in/dxEV5KiY #abbvie #ADC #antibodydrugconjugates #bioconjugates #biopharma #biologics #biotech

Since its initial public offering at $14.75 in 2020, Lantern Pharma Inc. (Nasdaq: LTRN)'s stock remained around $5 for the past two years. However, since March 1, it has nearly doubled in value as additional drugs progressed into trial phases. “It validates the model that goes after a patient population that is in need of affordable, available medicines,” Sharma says. “Our hope is that we can bring this model of velocity and efficiency across multiple cancer categories.” Learn more about how Lantern Pharma's cutting-edge AI is changing the game in healthcare in this DCEO Healthcare feature! https://lnkd.in/grVgJyks